Saxagliptin

Category: pharmacological

Aliases: Onglyza

Pharmacological Mechanism

DPP-4 inhibitor — raises endogenous GLP-1 + GIP, promoting glucose-dependent insulin release. CYP3A4/5 substrate. Modest A1c reduction (~0.5%); slight heart failure signal vs sitagliptin.

Half-Life (t½)

PO: 3h

Dosing Guidelines

• PO: Typical 5mg (Range: 2.5 - 5 mg)

Target Organ Systems

• cardiovascular
• endocrine
• digestive